These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38726264)

  • 21. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
    Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MCAK Inhibitors Induce Aneuploidy in Triple-Negative Breast Cancer Models.
    Smith JC; Husted S; Pilrose J; Ems-McClung SC; Stout JR; Carpenter RL; Walczak CE
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
    Wawruszak A; Luszczki J; Okon E; Czerwonka A; Stepulak A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
    Ge LP; Jin X; Yang YS; Liu XY; Shao ZM; Di GH; Jiang YZ
    Oncogene; 2021 Mar; 40(12):2323-2334. PubMed ID: 33654196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
    Bao B; Prasad AS
    Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
    Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
    He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
    PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer.
    Kwon A; Lee GB; Park T; Lee JH; Ko P; You E; Ahn JH; Eom SH; Rhee S; Song WK
    Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32917017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule agents for triple negative breast cancer: Current status and future prospects.
    Ou Y; Wang M; Xu Q; Sun B; Jia Y
    Transl Oncol; 2024 Mar; 41():101893. PubMed ID: 38290250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.
    Al-Ejeh F; Simpson PT; Sanus JM; Klein K; Kalimutho M; Shi W; Miranda M; Kutasovic J; Raghavendra A; Madore J; Reid L; Krause L; Chenevix-Trench G; Lakhani SR; Khanna KK
    Oncogenesis; 2014 Apr; 3(4):e100. PubMed ID: 24752235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.